{
    "name": "oseltamivir",
    "comment": "Rx",
    "other_names": [
        "Tamiflu"
    ],
    "classes": [
        "Antivirals",
        "Influenza",
        "Neuraminidase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/tamiflu-oseltamivir-342618",
    "pregnancy": {
        "common": [
            "There are no adequate and well–controlled studies in pregnant women to inform a drug–associated risk of adverse developmental outcomes; available published epidemiological data suggest that the drug, taken in any trimester, is not associated with an increased risk of birth defects; however, these studies individually are limited by small sample sizes, use of different comparison groups, and some lacked information on dose, which preclude a definitive assessment of the risk",
            "Pregnant women are at higher risk of severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes including maternal death, still births, birth defects, preterm delivery, low birth weight and small for gestational age"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, no adverse developmental effects were observed at clinically relevant exposures"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Based on limited published data, have shown the drug to be present in human milk at low levels considered unlikely to lead to toxicity in the breastfed infant; postmarketing experience has not reported any information to suggest serious adverse effects to drug exposure via breast milk in infants; it is not known if drug affects human milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in patients with chronic cardiac disease, severre hepatic impairment, renal imapairment, respiratory disease",
                "Delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes, reported in patients with influenza who were receiving therapy; relationship to therapy not established",
                "Most effective when used within 24-48 hr of onset of symptoms",
                "Safety and efficacy for prophylaxis of influenza not established for <1year of age",
                "Oral suspension should be mixed prior to dispensing",
                "Safety and efficacy in immunocompromised patients not established",
                "Therapy is not a substitute for influenza virus vaccine",
                "Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme; discontinue therapy and initiate appropriate treatment if allergic-like reactions occur or are suspected",
                "Prescribers should be alert to potential for secondary bacterial infections and treat them as appropriate"
            ],
            "specific": [
                {
                    "type": "Neuropsychiatric events",
                    "description": [
                        "Delirium and abnormal behavior leading to injury, including fatalities, reported postmarketing in patients with influenza receiving oseltamivir",
                        "Because these events were reported voluntarily during clinical practice, frequency cannot be estimated, but occurrence is uncommon",
                        "Reported primarily among pediatric patients and often had an abrupt onset and rapid resolution",
                        "Unable to establish causality between these events and oseltamivir",
                        "These events may occur in the setting of encephalitis or encephalopathy, but can occur without obvious severe disease; closely monitor oseltamivir-treated patients with influenza for signs of abnormal behavior"
                    ]
                },
                {
                    "type": "Oral suspension and hereditary fructose intolerance",
                    "description": [
                        "Fructose can be harmful to patients with hereditary fructose intolerance",
                        "One dose of 75 mg oral suspension delivers 2 g of sorbitol; this is above the daily maximum limit of sorbitol for patients with hereditary fructose intolerance, and may cause dyspepsia and diarrhea"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "pretomanid will increase the level or effect of oseltamivir by  Other (see comment). Avoid or Use Alternate Drug. In vitro studies demonstrated that pretomanid significantly inhibits OAT3; monitor for increased adverse effects and consider dosage reduction for OAT3 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "clopidogrel decreases levels of oseltamivir by Other (see comment). Use Caution/Monitor. \nComment: Clopidogrel may decrease serum concentrations of active metabolite(s) of oseltamivir. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine quadrivalent, cell-cultured by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, recombinant",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, recombinant",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid increases levels of oseltamivir by Other (see comment). Use Caution/Monitor. \nComment: Coadministration of probenecid results in a 2-fold increase in exposure to oseltamivir carboxylate because of a decrease in active anionic tubular secretion in the kidney. No dosage adjustments are required with probenecid coadministration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of oseltamivir by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Abdominal pain",
            "percent": "2"
        },
        {
            "name": "Conjunctivitis",
            "percent": "1"
        },
        {
            "name": "Ear disorder",
            "percent": null
        },
        {
            "name": "Epistaxis",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Aggravation of diabetes",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Arrhythmia",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Delirium",
            "percent": null
        },
        {
            "name": "Hemorrhagic colitis",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "Humerus fracture",
            "percent": null
        },
        {
            "name": "Peritonsillar abscess",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Pseudomembranous colitis",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "Transaminases increased",
            "percent": null
        },
        {
            "name": "Toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Unstable angina",
            "percent": null
        },
        {
            "name": "Swelling of face or tongue",
            "percent": null
        },
        {
            "name": "Hypothermia",
            "percent": null
        },
        {
            "name": "Diaper rash",
            "percent": null
        },
        {
            "name": "weeks to",
            "percent": null
        },
        {
            "name": "year of age",
            "percent": null
        },
        {
            "name": "Dermatitis",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Eczema",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson Syndrome",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Gastrointestinal bleeding",
            "percent": null
        },
        {
            "name": "Abnormal liver function tests",
            "percent": null
        }
    ]
}